https://www.yiliao.com/index.php?action=history&feed=atom&title=CAR-T_%E6%AF%92%E6%80%A7%E7%AE%A1%E7%90%86
CAR-T 毒性管理 - 版本历史
2026-04-18T16:17:50Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=CAR-T_%E6%AF%92%E6%80%A7%E7%AE%A1%E7%90%86&diff=311265&oldid=prev
223.160.136.32：建立内容为“<div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T01:49:47Z
<p>建立内容为“<div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff;"><br />
<br />
<div style="margin-bottom: 20px; border-bottom: 1px solid #f1f5f9; padding-bottom: 15px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155;"><br />
<strong>CAR-T 毒性管理</strong>（CAR-T Toxicity Management）是指在[[嵌合抗原受体T细胞]]（CAR-T）回输后，针对其诱发的全身性免疫损伤进行的系统性监测与干预。其核心挑战在于平衡抗肿瘤效应与致命性毒副反应，重点包括[[细胞因子释放综合征]]（CRS）及[[免疫效应细胞相关神经毒性综合征]]（ICANS）。现代管理策略依托 ASTCT 分级标准，通过精准的免疫抑制手段实现临床获益最大化。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 100%; max-width: 340px; margin: 0 auto 30px auto; border: 1px solid #cbd5e1; border-radius: 12px; background-color: #ffffff; box-shadow: 0 10px 25px rgba(0,0,0,0.08); overflow: hidden;"><br />
<br />
<div style="padding: 18px 15px; color: #ffffff; background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.25em; font-weight: bold; letter-spacing: 1px; text-decoration: none !important;">CAR-T 毒性 · 管理手册</div><br />
<div style="font-size: 0.75em; opacity: 0.8; margin-top: 4px; white-space: nowrap; text-decoration: none !important;">Toxicity Management (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 35px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 20px; padding: 25px; box-shadow: 0 4px 10px rgba(0,0,0,0.03);"><br />
[[文件:CAR-T_Toxicity_Clinical_Icon.png|110px|CAR-T 毒性临床管理]]<br />
</div><br />
<div style="font-size: 0.85em; color: #64748b; margin-top: 15px; font-weight: 600;">CRS 与 ICANS 动态监测模型</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.9em;"><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #64748b; font-weight: 600; width: 40%; background-color: #fcfdfe;">主要毒性</th><br />
<td style="padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #1e293b;">CRS, ICANS, 细胞减少</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #64748b; font-weight: 600; background-color: #fcfdfe;">评价体系</th><br />
<td style="padding: 10px 18px; border-bottom: 1px solid #f1f5f9; color: #1e293b;">[[ASTCT 分级指南]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 18px; color: #64748b; font-weight: 600; background-color: #fcfdfe;">核心药物</th><br />
<td style="padding: 10px 18px; color: #1e293b; font-weight: bold;">[[托珠单抗]], [[地塞米松]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">毒性发生的病理生理基础</h2><br />
<br />
<p style="margin: 15px 0;"><br />
CAR-T 毒性源于强烈的靶向性免疫激活，其病理机制并非单一的 T 细胞毒性，而是涉及多种细胞因子与旁路细胞的互动：<br />
</p><br />
<ul style="padding-left: 20px; color: #475569;"><br />
<li style="margin-bottom: 10px;"><strong>细胞因子风暴级联：</strong> CAR-T 激活后释放 IFN-γ，诱导宿主[[巨噬细胞]]产生大量 [[IL-6]] 和 IL-1，这是 CRS 临床进展的主要驱动力。</li><br />
<li style="margin-bottom: 10px;"><strong>内皮细胞活化：</strong> 系统性炎症导致内皮细胞受损及血管通透性增加，严重时引发[[毛细血管渗漏综合征]]。</li><br />
<li style="margin-bottom: 10px;"><strong>血脑屏障破坏：</strong> 循环中高水平的促炎因子及浸润的免疫细胞进入脑实质，触发 [[ICANS]]。</li><br />
</ul><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">核心毒性分级与干预策略</h2><br />
<br />
<br />
<h3 style="color: #1e40af; border-bottom: 2px solid #dbeafe; display: inline-block; padding-bottom: 3px; margin-top: 20px;">1. CRS 的分阶管理</h3><br />
<p style="margin: 10px 0;"><br />
CRS 管理遵循“早发现、阶梯式干预”的原则：<br />
</p><br />
<ul style="padding-left: 20px; color: #475569;"><br />
<li style="margin-bottom: 8px;"><strong>1级：</strong> 对症支持（如退热药物）。</li><br />
<li style="margin-bottom: 8px;"><strong>≥2级：</strong> 引入 [[托珠单抗]] (Anti-IL-6R)；若持续不缓解，加用[[地塞米松]]。</li><br />
<li style="margin-bottom: 8px;"><strong>危重症：</strong> 考虑联合[[阿那白滞素]] (Anti-IL-1) 或[[血浆置换]]。</li><br />
</ul><br />
<br />
<h3 style="color: #1e40af; border-bottom: 2px solid #dbeafe; display: inline-block; padding-bottom: 3px; margin-top: 20px;">2. ICANS 的神经保护</h3><br />
<br />
<p style="margin: 10px 0;"><br />
由于托珠单抗难以穿透血脑屏障，且可能导致外周 IL-6 向中枢代偿性升高，ICANS 的首选药物为**糖皮质激素**而非托珠单抗。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 85%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1px solid #e2e8f0; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #1e3a8a;"><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">毒性类别</th><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">关键生物标志物</th><br />
<th style="padding: 12px; border: 1px solid #e2e8f0; color: #1e3a8a;">首选药物逻辑</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #e2e8f0; background: #fcfdfe; font-weight: bold;">CRS</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">[[CRP]], [[铁蛋白]], IL-6</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">托珠单抗 (IL-6R 阻断)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #e2e8f0; background: #fcfdfe; font-weight: bold;">ICANS</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">ICE 评分, 脑脊液蛋白</td><br />
<td style="padding: 10px; border: 1px solid #e2e8f0;">地塞米松 (控制脑水肿)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: linear-gradient(to right, #1e3a8a, #ffffff); color: #ffffff; padding: 8px 15px; border-radius: 4px; font-size: 1.2em; margin-top: 35px; text-decoration: none !important;">前沿进展：预测与预防性干预</h2><br />
<p style="margin: 15px 0;"><br />
现代 CAR-T 研发越来越注重从“治疗毒性”向“预防毒性”转化：<br />
</p><br />
<ul style="padding-left: 20px; color: #475569;"><br />
<li style="margin-bottom: 10px;"><strong>预防性给药：</strong> 对于肿瘤负荷极高的患者，预先使用托珠单抗可能显著降低严重 CRS 的发生率。</li><br />
<li style="margin-bottom: 10px;"><strong>结构优化：</strong> 开发带有“自杀开关”或采用低亲和力 scFv 结构的 CAR-T，以减缓细胞因子释放速度。</li><br />
</ul><br />
<br />
<div style="font-size: 0.85em; line-height: 1.8; color: #94a3b8; margin-top: 40px; border-top: 2px solid #f1f5f9; padding-top: 15px;"><br />
<p style="margin-bottom: 8px;"><br />
[1] Lee DW, et al. "ASTCT Consensus Grading for Cytokine Release Syndrome and ICANS." <em>BBMT</em>. 2019. <br />
<span style="color: #64748b;">(点评：全球 CAR-T 毒性管理的“金标准”，统一了临床评判语言。)</span><br />
</p><br />
<p style="margin-bottom: 8px;"><br />
[2] Neelapu SS, et al. "Chimeric antigen receptor T-cell therapy — assessment and management of toxicities." <em>Nat Rev Clin Oncol</em>. 2018. <br />
<span style="color: #64748b;">(点评：深度解析了 CAR-T 临床应用中的综合安全管理，具有极强的实操指导意义。)</span><br />
</p><br />
<p style="margin-bottom: 8px;"><br />
[3] Santomasso BD, et al. "The Biology of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)." <em>Cancer Discovery</em>. 2020. <br />
<span style="color: #64748b;">(点评：阐述了 ICANS 发生的血脑屏障机制及内皮细胞活化在神经毒性中的关键作用。)</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #1e3a8a; border-radius: 8px; overflow: hidden; font-size: 0.9em;"><br />
<div style="background-color: #1e3a8a; color: #ffffff; text-align: center; font-weight: bold; padding: 12px; text-decoration: none !important;">CAR-T 安全性导航</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2; text-align: center;"><br />
[[ASTCT 分级]] • [[托珠单抗]] • [[ICANS]] • [[细胞因子风暴]] • [[阿那白滞素]]<br />
</div><br />
</div><br />
<br />
</div></div>
223.160.136.32